- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 334
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 12,508
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Interventions
- Plixorafenib
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
- Conditions
- Multiple Myeloma Refractory, Multiple Myeloma in Relapse
- Interventions
- InoPd, Investigator's choice of SAT
- Drug
- Lead sponsor
- CellCentric Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Bacterial Vaginosis
- Interventions
- DARE-BV1clindamycin phosphate vaginal gel, 2%
- Drug
- Lead sponsor
- Daré Bioscience, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 56
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Castrate-Resistant Prostate Cancer
- Interventions
- ISIS EIF4E Rx, Prednisone, Docetaxel
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more
- Conditions
- Alzheimer's Disease
- Interventions
- LY3202626, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 49
- States / cities
- Irvine, California • Sacramento, California • San Diego, California + 40 more
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Iberdomide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more
- Conditions
- HIV Disease
- Interventions
- HAART regimen, 3TC or FTC monotherapy
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 8 Years to 24 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more
- Conditions
- Carcinoma of Unknown Primary
- Interventions
- radiation therapy
- Radiation
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 237
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
- Conditions
- Esophageal Cancer
- Interventions
- cetuximab, cisplatin, irinotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 132
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1023
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
- Conditions
- Cardiovascular Disease, Diabetes Mellitus Type 2
- Interventions
- Placebo, aleglitazar
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 143
- States / cities
- Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- HIV
- Interventions
- TEAM
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- OpSCF, Placebo
- Biological
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more
- Conditions
- Corneal Epithelial Disorders
- Interventions
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Drug
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 30 more
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
- Conditions
- Stomatitis
- Interventions
- EC-18, Placebo
- Drug
- Lead sponsor
- Enzychem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 20
- States / cities
- Long Beach, California • Los Angeles, California • Miami, Florida + 16 more
- Conditions
- Acute Pain
- Interventions
- Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo
- Drug · Other
- Lead sponsor
- Grünenthal GmbH
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Stanford, California • Miami, Florida + 9 more
- Conditions
- Parkinson Disease
- Interventions
- Omnidirectional stimulation, Directional stimulation
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 21
- States / cities
- Sacramento, California • Aurora, Colorado • Gainesville, Florida + 16 more
- Conditions
- Chronic Sinusitis
- Interventions
- Propel Nova Sinus Implant
- Device
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Miami, Florida • Dublin, Ohio